Brief: HanAll Biopharma Reports First Quarter Results
28/04/2023 12:21
April 28 (Reuters) - Hanall Biopharma Co Ltd
009420.KS :
* HANALL BIOPHARMA REPORTS FIRST QUARTER RESULTS AND
PROVIDES
BUSINESS UPDATE
* HANALL BIOPHARMA CO LTD - QTRLY REVENUE OF KRW 28.8
BILLION, UP
BY 20 PERCENT COMPARED TO SAME PERIOD IN 2022
* HANALL BIOPHARMA CO LTD- ON TRACK WITH ITS ONGOING PIVOTAL
PHASE
3 CLINICAL STUDY OF TANFANERCEPT (VELOS-3) IN DRY EYE DISEASE IN
FIRST HALF OF 2023
Source text for Eikon: ID:nPn9SXs0ca
Further company coverage: 009420.KS
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies